International journal of laboratory hematology · 2026
Assessment of Tfh Cells and Related Molecules in CML-CP Patients With Different Molecular Responses.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yulian, Geng Suxia, Chen Xiaomei, Huang Lisi, Huang Xin, Luo Qiong, Zeng Lingji, Wu Ping, Zhang Yuchen, Liu Kaifan, Du Xin, Weng Jianyu, Lai Peilong
Аннотация
INTRODUCTION: This study aimed to characterize T follicular helper (Tfh) cell differentiation and related molecular profiles in chronic-phase chronic myeloid leukemia (CML-CP) patients with distinct molecular responses and to explore immune correlates of treatment outcomes.
METHODS: Peripheral blood CD4+ T cells were analyzed in 125 CML-CP patients (8 newly diagnosed, 71 MMR, and 46 pre-MMR) and 22 healthy donors. We assessed CD4+ T subset distribution and expression of Tfh-related molecules including Bcl6, Blimp1, PD-1, PD-L1, and PD-L2.
RESULTS: Newly diagnosed and pre-MMR patients exhibited decreased CD4+ T cell proportions compared to healthy donors and MMR patients (p < 0.05), while pre-MMR patients had elevated frequencies of CD4+CXCR5+PD-1+ Tfh cells and increased PD-1 expression on CD4+ T cells (p < 0.05). Bcl6, PD-1, and PD-L1 were upregulated in pre-MMR cases, whereas Blimp1 and PD-L2 remained unaltered.
CONCLUSION: Pre-MMR CML-CP is accompanied by aberrant Tfh cell differentiation and an immunosuppressive immune signature linked to suboptimal molecular responses. Targeting immune checkpoints or modulating Tfh cell homeostasis may help improve therapeutic outcomes in CML-CP.
METHODS: Peripheral blood CD4+ T cells were analyzed in 125 CML-CP patients (8 newly diagnosed, 71 MMR, and 46 pre-MMR) and 22 healthy donors. We assessed CD4+ T subset distribution and expression of Tfh-related molecules including Bcl6, Blimp1, PD-1, PD-L1, and PD-L2.
RESULTS: Newly diagnosed and pre-MMR patients exhibited decreased CD4+ T cell proportions compared to healthy donors and MMR patients (p < 0.05), while pre-MMR patients had elevated frequencies of CD4+CXCR5+PD-1+ Tfh cells and increased PD-1 expression on CD4+ T cells (p < 0.05). Bcl6, PD-1, and PD-L1 were upregulated in pre-MMR cases, whereas Blimp1 and PD-L2 remained unaltered.
CONCLUSION: Pre-MMR CML-CP is accompanied by aberrant Tfh cell differentiation and an immunosuppressive immune signature linked to suboptimal molecular responses. Targeting immune checkpoints or modulating Tfh cell homeostasis may help improve therapeutic outcomes in CML-CP.